Melanoma Research Alliance Progress Report 2013–2014
Contents About Us
4
Science
7
Policy
16
Partnerships & Support
18
Events
21
Outreach & Communications
24
Supporters & Financials
28
1
#1 Grant Giving
Disease Foundation
Letter From the Chair & President This year has seen game-changing progress on behalf of melanoma patients. New treatments are saving lives and providing real hope that we are closer than ever to our goal of eliminating suffering and death from melanoma.
treatment of melanoma, including the first antiPD-1 drugs, dramatically improving the outlook for patients. Melanoma research has energized the entire field of oncology and charted a new course in cancer treatment for a variety of tumor types.
At the Melanoma Research Alliance (MRA), we are committed to funding cutting-edge research to speed the delivery of cures for all melanoma patients and everyone at risk for this deadly disease.
This report summarizes our many exciting accomplishments over the past 12 months and puts in perspective our strategy to capitalize on the progress made. We know that our work is not yet finished, as existing treatments still benefit too few melanoma patients, and there is much left to do in identifying better ways to prevent, detect and treat this disease. Through partnerships with all stakeholders and a firm commitment to fund the most impactful scientific research, we are building on the momentum in the field and leading the way toward revolutionary approaches in cancer treatment. We are grateful to the many individuals, organizations, government leaders, and companies whose support has enabled us to have enormous impact. Together, with your support, we will defeat melanoma.
In 2014, MRA awarded a historic $11 million in research funding to 34 investigators at 19 academic institutions, increasing MRA’s cumulative total funding since we began in 2007 to more than $60 million. MRA’s investment has catalyzed an additional $66 million in leveraged funding from other sources, which brings the total applied to melanoma research as a result of MRA to $126 million. The field of melanoma research has never been more exciting, thanks to recent success with the dual approaches of targeted therapies and immunotherapy treatment. MRA’s leadership in funding transformative research has accelerated the development of these novel approaches, funding critical studies that evaluate combinations, mechanisms of action and resistance, and biomarkers. Since MRA’s launch in 2007, seven new therapies have come onto the market for the
Debra Black Chair and Co-Founder
Wendy Selig President and CEO
3
About Us “MRA’s sophisticated model has improved outlooks for patients on multiple fronts. It is the most effective organization driving melanoma research in the world—and a textbook example of what a disease-specific organization should look like.” – Michael Milken, MRA Board Member and Milken Institute Chairman
The Melanoma Research Alliance (MRA) is a unique foundation launched in 2007 by Debra and Leon Black with a clear mission—to end suffering and death caused by melanoma, the deadliest form of skin cancer. By collaborating with all stakeholders, MRA directs critical resources to accelerate powerful research, advance cures for all patients and prevent more melanomas. Due to the generosity of MRA’s founders, 100% of all donations support MRA’s scientific programs. The incidence of skin cancer is rising. In the United States, melanoma rates have tripled over the last three decades. Defeating melanoma has become a public health imperative. Today, we are facing a skin cancer epidemic, but there is cause for hope. MRA is working to change the landscape for patients with melanoma and everyone who is at risk. But we need global support and collaboration to achieve this mission.
Join us, and help us win the fight against melanoma.
4
Hallmarks of the Program Key aspects of the MRA research portfolio include:
1 2 3 4
Encouraging Collaborative Team Science Team Science Awards fund multidisciplinary research groups and account for 70 percent of research funding to date, followed by a variety of individual awards.
Funding the Best and Growing the Field As of July 2014, MRA has funded 209 Principal Investigators (PIs) at 92 institutions in 14 countries, and more than half of the PIs awarded per year are new investigators to MRA.
Supporting Young Investigators The Young Investigator Awards program focuses on attracting and supporting the next generation of melanoma research leaders and has grown to 56 MRA young investigators to date.
Investing in Accelerating New Treatments Approximately 88 percent of research funding is directed at melanoma treatment science, with 18 clinical trials and 46 treatment approaches supported, including every melanoma treatment approved since 2011. Notably, owing to MRA’s support of $26M in immunotherapy research, MRA has advanced the field’s knowledge of immune checkpoint inhibitors targeting CTLA4 and PD-1 that is being rapidly translated beyond melanoma to many other cancer types.
5
MRA Research Funding Per Year: $11.4M $10.6M
$10M
$8.4M
$8.6M
$7.9M
$7.6M
$5.9M
$5M
$0 2008
6
About Us
2009
2010
2011
2012
2013
2014
Science Update on Science and Treatment Landscape Historically, options for patients with metastatic melanoma have been severely limited, but MRA’s research investments are improving the understanding and application of therapeutic agents and approaches. Many of these advances also spotlight melanoma as a case study for new treatment modalities for all of oncology. Seven new melanoma therapies have been approved since MRA’s launch in 2007, including the first immune checkpoint blocking drug (ipilimumab), the first molecularly targeted therapy (vemurafenib) and its companion diagnostic, as well as dabrafenib and trametinib as single agents in 2013 and in 2014 as the first combination therapy for melanoma. In 2014, the “next generation” immune checkpoint blocking agents targeting PD-1 have come onto the market and are showing great promise in many other cancers as well.
“When we started this, the best treatment we had was chemotherapy. In these seven years, everything’s changed. We now have active immunotherapy for the first time that actually improves survival. And all of a sudden, chemotherapy is second-, third- or fourth-line treatment for melanoma.” – Paul Chapman, M.D., Chair of MRA’s Medical Advisory Panel
7
Funding by Award Type & Scientific Area MRA provides support for cutting-edge translational research programs anywhere in the world that have the potential to transform the field. The majority of MRA’s investment is focused on treatment science, including studies to improve current therapies by identifying new biomarkers and combining treatments aimed at countering drug resistance. MRA is also focused on discovering new and more effective drug targets. The importance of these projects is to understand how to achieve superior therapeutic results with the agents used either singly or in combination and to determine which patients will benefit from therapies. MRA also supports the development of prevention strategies and the identification of new biomarkers for prognostics and staging.
Commitments in Research
$3.8 M Diagnosis/ Staging
8
Science
$3.6 M Prevention
$53 M
Treatment
Funded to Date:
47 Teams
32
Established Investigators
56
Young Investigators
12
Pilot & Development Projects
11
Academic-Industry Partnerships
Team Science Awards fulfill one of MRA’s primary goals: to foster a collaborative research process. Multidisciplinary teams consist of Principal Investigators with complementary expertise from the same institution, inter-institutional, and/or international. Team science projects promote transformational melanoma research advances with the potential for rapid clinical translation.
Established Investigator Awards support investigators with an established record of scientific productivity and accomplishment and who are past the initial four years of their first academic faculty appointment.
Young Investigator Programs aim to attract early career scientists with novel ideas into melanoma research, thereby recruiting and supporting the next generation of melanoma researcher leaders. Young Investigators are scientists within four years of their first academic faculty appointment. A mentorship commitment from a senior investigator is required.
Pilot Awards fund potentially transformative ideas that do not have extensive preliminary data but articulate a clear hypothesis and translational goals. Resources for such “high-risk, high-reward” projects are important to establish proof-of-concept, which may then leverage additional funding through more traditional avenues. Development awards are a subtype in which one year of funding is provided.
Academic-Industry Partnership Awards are designed to facilitate interactions between the academic and industrial research sectors, and are co-supported by MRA and an industrial partner whose involvement is essential to the project.
9
Improving the Understanding & Treatment of Melanoma Brain Metastases Brain metastases are one of the most difficult-to-treat complications of melanoma. To develop effective therapies, more information is needed about how melanoma is able to spread and grow in the brain. MRA is supporting programs totaling $2.1 million in research funding to advance this area of critical unmet need. Michael Davies, M.D., Ph.D., at the University of Texas MD Anderson Cancer Center, with the support of an MRA Young Investigator Award, found that melanomas that grow in the brain exhibit unique molecular features compared to metastases at other sites in the body, even in the same patient. Dr. Davies’ subsequent Team Science Award is supporting a novel study to investigate a BRAF inhibitor alone or in combination with a MEK inhibitor in patients to understand how well the treatment is able to penetrate brain tumors and to determine possible mechanisms that the tumors might use to develop resistance against this therapy. Findings from Dr. Davies’ studies, and other MRA-funded research in this area, have informed and accelerated clinical trials for patients.
Total Funding by Award Type, 2008-2014
Team Science: $41.5M Established Investigator: $7.6M Young Investigator: $7.2M Pilot / Development: $1.0M Partnership: $3.1M
10
Science
MRA Progress Metrics In just seven years of active research, the productivity of MRA-funded investigators has been high, as measured by tangible outcomes and promising early results that have advanced the understanding of the melanoma initiation and progression and the development of new therapies for patients:
$
66M
clinical trials to test new melanoma treatments
in leveraged funding raised from government, industry and other sources
21
125
patent applications filed for new research and treatment technology
papers published in highimpact journals describing results of MRA research
600
170
investigator presentations delivered at conferences around the world
new collaborations initiated and strengthened between academia, government and industry
11
Leveraged Funding
MRA Investment
$60.5 M
Leveraged Funding
Advancing Immunotherapy in Melanoma and Other Cancers MRA-funded research has been central to advancing a particularly promising class of molecules that boosts the immune system against melanoma. These agents, socalled immune checkpoint inhibitors, include the FDA-approved anti-CTLA4 agent ipilimumab and the anti-PD-1 agent pembrolizumab. The data that MRA-funded scientists have generated in understanding anti-PD-1 antibodies is now being used by cancer researchers working on colon, breast, brain, pancreatic, kidney, prostate, bladder, leukemia, lymphoma and lung cancer immunotherapy. With $13 million in support focusing on immune checkpoint inhibitors from MRA since 2008, researchers are focused on further understanding the mechanisms underlying therapy, identifying treatment-related biomarkers, and developing combinatorial therapy approaches. An MRA Team Science Academic-Industry Partnership Award being led by Jedd Wolchok, M.D., Ph.D., at Memorial Sloan Kettering Cancer Center is supporting research in this area, defining the mechanisms for the potential synergistic effect of the anti-PD-1 agent nivolumab with ipilimumab that will help determine which patients will benefit most from this combination strategy.
12
Science
$66.0 M
Global Presence MRA seeks out opportunities to connect researchers across multiple continents, supporting promising projects around the world. To date, MRA research awards have supported 92 institutions in 14 countries, highlighting the commitment to the global fight against melanoma.
United States, Australia, Belgium, Canada, England, France, Germany, Israel, Netherlands, New Zealand, Norway, Spain, Sweden, Switzerland
In 2014, MRA joined with the Saban Family Foundation to provide funding for three interdisciplinary teams, each led by a Principal Investigator at an institution in Israel. One of the Saban Family Foundation-MRA Team Science Awards includes funding for investigators at the Hebrew University of Jerusalem, the University of Colorado and the University of North Carolina to study new melanoma therapeutic targets. International collaborations such as these are needed to spark new ideas and accelerate time frames to improve the treatment of melanoma. These Team Science Awards represent the first regionally targeted funding opportunity for MRA and illustrate why collaboration and global reach are essential in the fight against melanoma.
13
Annual Scientific Retreat In February 2014, MRA convened its Sixth Annual Scientific Retreat in Washington, DC. The retreat brought together more than 300 leaders from academia, industry, nonprofits, and government to share early findings, identify future directions, discuss ideas and look for synergies and partnerships. MRA was joined by a number of individuals from around the world representing 77 institutions, 29 companies, more than a dozen collaborating foundations and many engaged patients. Retreat attendees heard results from the world’s leading melanoma researchers, as well as testimonials from melanoma patients directly impacted by this work. MRA hosted a solutionsoriented session with industry and FDA to promote new models for advancing earlier stage therapies and presented a lunchtime discussion
14
Science
panel featuring Milken Institute Chairman Michael Milken and former U.S. Senator Connie Mack, both MRA Board Members, and journalist and author Cokie Roberts. This year, MRA also convened a meeting of skin cancer and melanoma foundations, providing the coalition with a forum for sharing best practices and a platform to co-fund MRA-vetted research. MRA published Converging on a Cure, summarizing the meeting highlights, emphasizing the importance of cross-sector and inter-disciplinary collaborations, catalyzed by MRA’s model of engaging the leaders in the field.
“I was extremely impressed with the high level of the scientific presentations. It was encouraging to see the active participation of academic, industry, and government groups—an ideal process for accelerating the pace of development and registration of melanoma treatment options.” – Tom Hall, Senior Principal Scientist, Pfizer
15
Policy MRA is uniquely positioned to leverage its scientific credibility and reach in the public policy arena to advance better prevention, detection and treatment approaches. MRA has led and contributed to a number of efforts aimed at policy-makers, urging them to help in the fight against deadly skin cancer.
16
Regulatory Engagement
Surgeon General’s Call to Action
By working collaboratively with the FDA and industry, MRA addresses key regulatory roadblocks that challenge the development of new cancer therapies and devices, including issues relating to expanded access through clinical trials and compassionate use. MRA leadership has provided guidance to the FDA in its implementation of the new “Breakthrough Therapies” designation, aimed to accelerate and streamline the process for drug approvals. Additionally, MRA continues to engage senior FDA leadership in strategic discussions to speed patients’ access to new treatment options.
MRA has been central to engaging public health leaders in a melanoma prevention strategy. These efforts spurred the development and recent publication of a Surgeon General’s Call to Action on Preventing Skin Cancer, released in July 2014.
Tanning Bed Bans for Minors / Reclassification MRA strongly supports efforts among federal and state legislatures to reduce the use of indoor tanning devices. Today, 11 states across the U.S. have adopted bans that prohibit minors under 18 years of age from using indoor tanning beds. At the federal level, MRA was an active proponent of the reclassification of tanning beds from Class 1 (low risk) to Class 2 (moderate risk) devices.
“MRA provides unique scientific leadership and policy expertise. We relied on MRA as a leading member of our successful coalition effort to enact legislation that will bring innovative new sunscreen products to Americans and help prevent melanoma.” – Michael J. Werner, Partner, Holland & Knight, LLP
PASS Coalition MRA is an active member of the Public Access to SunScreens (PASS) Coalition whose goal is to work collaboratively with the FDA, the White House, Congress, health providers, consumer organizations and sunscreen manufacturers to establish a transparent process for pre-market approval of sunscreen ingredients. The Coalition’s efforts led to the passage of the Sunscreen Innovation Act, bipartisan legislation that alleviates the 12-year backlog of ingredients to ensure the public has access to innovative sunscreen products.
Department of Defense and NIH Funding for Research MRA is a leading member of several influential coalitions, such as United for Medical Research (UMR) and the National Coalition for Cancer Research (NCCR), the Alliance for a Stronger FDA, and Research!America, whose ongoing efforts advocate for sustained funding increases at the FDA, NIH, and National Cancer Institute (NCI). Working in collaboration with other organizations, MRA has been instrumental in urging Congress to provide additional research funding for melanoma through the Department of Defense (DoD) Peer Reviewed Cancer Research Program. Recognition by the federal government of the direct link between the incidence of melanoma among our nation’s military and prolonged exposure to UV radiation during active service is an important step in fighting melanoma.
17
Partnerships & Support “MRA Academic-Industry Partnerships accelerate progress by co-funding research and facilitating academic and industry research collaboration to catalyze the next wave of innovation in melanoma.” – Jeff Legos, Ph.D., Vice President, Medicines Development Leader, GlaxoSmithKline Oncology R&D
Our Approach Innovative partnerships remain central to MRA’s activities—from its team research funding approach to its allies who help the organization realize its vision. Since its inception, MRA has made great strides with its industry, corporate and non-profit allies program, establishing and growing collaborations with more than 100 organizations to fund research, increase sun safety awareness and support policy initiatives.
Collaborative Funding Model In 2012, MRA began pioneering a novel collaborative funding program with academic institutions around the world to pursue matched support for scientifically meritorious research that falls outside MRA’s full funding pay line. Through this vehicle, MRA can stretch its resources to support a greater number of research projects, engage new donors in MRA’s work, recruit melanoma researchers and encourage the growth of institutional melanoma programs. MRA introduced the model in 2013 through a partnership with Duke University to fund a Young Investigator Award. Since then, MRA has greatly expanded the pilot program to involve eight other academic institutions. As a result of these efforts, MRA has raised approximately $2 million for research projects that would have otherwise not received support. MRA strives to continue to shepherd this program around the world, demonstrate the capacity to co-fund through this novel mechanism and improve and adjust it year after year.
18
Collaborative Funding Testimonial: Sonja Plesset, Ph.D. Sonja Plesset is Vice President for Advancement at Whitehead Institute for Biomedical Research, a leading non-profit research institution dedicated to improving human health through biomedical research. In 2013, MRA launched its first partnership with Whitehead, supporting Whitehead Member Dr. Piyush Gupta through a collaboratively funded Young Investigator Award. When I first met with Dr. Piyush Gupta to discuss his melanoma research, I was shocked to learn that while there are targeted drugs for BRAF-mutated melanoma, resistance develops in 100% of patients. Moreover, nearly half of patients have a BRAF mutation. During my first call with MRA, I learned the organization was interested in translational work as well as high-risk, high-reward research supported by strong preliminary data. Piyush’s research seemed an excellent fit—and a particularly good match for MRA’s Young Investigator Award. We invited MRA to visit Whitehead Institute, and Piyush explained that despite improved patient outcomes, all patients eventually develop resistance to BRAF-targeting treatments, and six to eight months after treatment, resistant cells emerge and cause relapse. He submitted a strong research proposal that outlined his strategy to revise these therapies, arguing that if he could identify the molecular mechanisms by which cancer cells tolerate BRAF inhibitors then, perhaps, he could use inhibitors of these found pathways in combination with approved BRAF inhibitors to prevent recurrence. We were delighted when the news arrived that MRA wished to support his research through the organization’s collaborative funding vehicle, and I am confident that this is the start of a very productive partnership. At the end of the day, our goals are completely aligned—we want to ensure Piyush has the funding he needs to complete his ambitious project, which could yield a novel combination therapy and improve outcomes in BRAF-mutated melanoma patients.
19
“Over the past four years, Sports Authority has partnered with MRA to educate the public on ways to reduce their risk of melanoma while raising funds to support its treatment and cause. Our annual point-of-sale donation campaign, coupled with MRA’s innovative program to spread awareness, encourages employees and shoppers to give back to melanoma research.” – Mike Foss, Chief Executive Officer, Sports Authority
20
Partnerships & Support
Events During the past year, MRA has continued to expand its funding scope by hosting gatherings across the country to engage new supporters and elevate the importance of melanoma among varied audiences.
21
Sotheby’s MRA’s third benefit dinner drew a devoted group of philanthropists, scientists and corporate allies to Sotheby’s New York City headquarters and raised a record-breaking $6 million. The evening featured addresses by MRA’s leadership and 2013 Young Investigator Tara Gangadhar, M.D. The live auction, led by Jamie Niven, Sotheby’s chairman of North and South America, was the pinnacle of the evening, with attendees pledging to support 11 new Young Investigator Awards.
22
Events
Leveraged Finance Fights Melanoma In recognition of Melanoma Awareness Month, individuals from Wall Street gathered to network and raise funds and awareness for melanoma at the third annual Leveraged Finance Fights Melanoma (LFFM) event at Rockefeller Center. MRA Board Member Michael Milken spoke at the 900-person event and the evening raised $1.4 million, surpassing last year’s totals for both attendees and funds raised.
23
Outreach & Communications MRA continues to gain visibility, funding and support through multifaceted approaches with the press and its corporate and foundation partners. MRA greatly enhanced its online presence from 2013 to 2014 through media opportunities, social media outreach and a series of self-branded informational and educational videos. On Facebook and Twitter, MRA’s scientific voice is increasingly acknowledged and echoed in messaging communications by pharmaceutical companies, research institutions and foundations and often intersects with its corporate allies’ promotional efforts. When compared to Melanoma Awareness Month in May 2013, MRA realized a 50% increase in website hits in May 2014, a 162% increase in the number of times its content was retweeted and a near doubling of Twitter followers.
24
L’Oréal Paris Partnership—Thunderclap L’Oréal Paris launched the “It’s THAT Worth It” Thunderclap campaign in the spring as part of an ongoing collaboration with MRA that is funding the MRA-L’Oréal Paris Team Science Award led by Dr. Meenhard Herlyn of Wistar Institute. The campaign culminated on May 20 when over 2,700 social media accounts jointly broadcast a synchronized message of melanoma awareness and support for MRA to a combined audience of over 7 million people. For each supporter who signed up for the Thunderclap, L’Oréal Paris donated $1 to MRA’s research program. The company also produced a collection of digital and print PSAs that highlighted the importance of daily sunscreen usage and featured celebrity spokespeople including Diane Keaton, Eva Longoria, Lea Michele and Aimee Mullins.
Stand Up To Cancer (SU2C) In 2012, MRA partnered with SU2C to fund a Melanoma Dream Team led by Drs. Jeffrey Trent and Patricia LoRusso. This year, MRA announced its second Dream Team collaboration with SU2C. Along with the Cancer Research Institute (CRI), this three-year $10 million Immunology Translational Research Dream Team led by Drs. James Allison and Antoni Ribas focuses on the complex relationship between cancer and the immune system, with the goal of enhancing immune-based therapies for cancer patients. MRA’s funding will support an extension of the team’s research into a melanoma-specific examination of the immune mechanisms underlying patients’ response to novel immunotherapies.
25
Melanoma Awareness Month—May 2014 May offered an important opportunity for MRA and its partners to advance the mission of reducing suffering and death from skin cancer. MRA partnered with 17 corporate partners to generate funding and awareness through cause marketing and outreach programs. These programs highlighted the dangers of melanoma, educated the public about how to reduce risk, and provided ways for people to take action. This past May, MRA’s sun safety and prevention messaging made more than 300 million impressions around the world.
Outreach and Fundraising Campaigns: TSA, American Idol® Live! For the fourth consecutive year, Sports Authority launched an in-store donation and consumer awareness program to raise funds for MRA’s research program and to help educate customers on ways to reduce their risk of melanoma. MRA also partnered for a second year with the American Idol Live! Tour 2014. For every ticket purchased for the Tour, American Idol Live! donated $1 to MRA. The Tour hit 40 different cities across the U.S. throughout the summer. Venues broadcast the aforementioned L’Oréal Paris PSAs at their shows to further underscore the partnership with MRA and encourage audience members to be sun safe.
Press Highlights MRA was ranked first out of the top 30 grant-giving disease foundations by Genetic Engineering & Biotechnology News. The ranking was determined by the percentage of total revenues each foundation devoted to grants and awards. MRA leadership was frequently sought out and featured in national news media outlets, including The Huffington Post, the Washington Post, CNN and Fox News for expert commentary on melanoma research, detection and prevention news.
#1 Grant Giving
Disease Foundation
Lifestyles magazine featured an in-depth profile of Co-founder and Board Chair Debra Black. MRA has been featured on the AOL homepage as the ‘Cause of the Day’ every year in May since 2012. The feature drove more than 11,000 visitors to the MRA website in 2014, outperforming AOL’s module average.
26
Outreach & Communications
Conference Engagement MRA leadership regularly engages in conferences around the world. In 2014, MRA was well-represented on “Cancer Immunotherapy: The Silver Bullet Against Cancer?” a panel at the Milken Institute Global Conference, which discussed developments and challenges in cancer immunotherapies.
Dermatology Council The MRA Dermatology Council was established in 2014 to engage leaders in the field of dermatology to advise, assist and make recommendations to MRA on matters related to prevention, diagnosis and early treatment of melanoma. By engaging further with these physicians in both academic and private practice, MRA expects to identify new opportunities for research, education and intervention. MRA also anticipates reaching a wider segment of the population by working with dermatologists on the frontline of melanoma care.
Looking Forward: Patient Engagement Program As MRA continues to accelerate progress and fulfill its mission of eliminating suffering and death due to melanoma, there is enhanced opportunity to expand the organization’s impact in the community through patient engagement activities. The goal of MRA’s new patient engagement program is to leverage MRA’s deep scientific and clinical reach and position MRA as a resource for newly diagnosed patients, individuals receiving treatment and those seeking to participate in clinical research. MRA has already initiated the first phase of these activities through the creation of two new educational videos on the latest advances in immunotherapy in collaboration with Health Guru and the development of an immunotherapy patient forum with other cancer foundations. 27
Supporters & Financials
28
Donors and Supporters 1/1/2013 to 12/31/2013 *Multi-year donor
h $500,000 Akin Gump Strauss Hauer & Feld LLP* The Jeffrey A. Altman Foundation* Debra and Leon Black* Bloomberg Philanthropies* Christie’s* Jeffrey Epstein VI Foundation Jami Gertz and Tony Ressler*
Hess Foundation, Inc.* L’Oréal Paris* Nancy and Howard Marks* The Stewart J. Rahr Foundation* The Ressler Family Foundation* Saban Family Foundation* Sokoloff Family Trust*
$250,000-$499,999
$100,000-$249,000
$50,000-$99,999
Bank of America*
Aon*
19 Entertainment
Bristol-Myers Squibb Company
The Bell Family Foundation, Inc.*
Anonymous
The Carson Family Charitable Trust*
Jill and Jay Bernstein*
Sunny and Norman Brownstein*
Credit Suisse*
Katie and Todd Boehly*
Ernst & Young*
Ellen and Gary Davis Foundation*
Brownstein, Hyatt, Farber & Schreck*
Goldman Sachs & Co.
GlaxoSmithKline*
Celgene
Judy and John Hannan
Hidary Foundation*
Claire’s Boutiques, Inc.
IPREO Debtdomain
Kirkland & Ellis LLP*
Deloitte*
Denise and Michael Kellen
Bennett S. LeBow*
Amanda and Jonathan Eilian*
Julie and Edward Minskoff
Paul, Weiss, Rifkind, Wharton & Garrison LLP*
The Ellis Family* Emilia Fanjul and Brian Pfeifler*
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.E.*
PricewaterhouseCoopers*
Larry Gagosian
Thomas Murphy
Mary Jo and Brian Rogers*
Daisy Helman*
Sandy and Paul Norman
Sotheby’s*
James O. Robbins Family Charitable Lead Annuity Trust*
O’Melveny & Myers LLP*
Elizabeth and Oliver Stanton Foundation*
Nancy and Richard Rogers
Vital Projects Fund, Inc.
US Trust, Bank of America, N.A.*
SkinCeuticals*
Wachtell, Lipton, Rosen & Katz*
The Viola Fund*
Sports Authority
Vinson & Elkins LLP*
Fran and Jeff Rowbottom
29
$25,000-$49,999
$5,000-$24,999
Fitch Ratings
Donna and William Acquavella
AdvaMedDx
Amgen, Inc.
Agenus, Inc.
Fried, Frank, Harris, Shriver & Jacobson LLP
Apollo Management, LP
Mark Albert
Debbie and Mark Attanasio
Alcenta
Emily and Len Blavatnik
American Securities Advisors LLC
BMO Capital Markets
Krista and Devon Archer
Cahill Gordon & Reindel LLP
Babson Capital Management LLC
Chapstick
Heather and Michael Baker
GoldenTree Asset Management, LP
Citi
Bank of America Merrill Lynch
Lee Grinberg
Joyce and Barry Cohen
Barclays Capital
Daiichi Sankyo
Melissa and Dror Bar-Ziv
H. Lee Moffitt Cancer Center & Research Institute
David L. Klein, Jr. Foundation
The Harper Family Foundation
The Derfner Foundation
Biotechnology Industry Organization
Eli Lilly and Company
BlackRock
HCA Holdings
Caryl and Israel Englander
Laura and Lloyd Blankfein
Ronnie F. Heyman
Paul J. Fribourg
The Blue Oak Charitable Fund
Genentech, Inc.
Katherine Boden Holland
Highbridge Capital Management, LLC
Gail and Carl Icahn
Michele and Fred Brettschneider
HSBC Bank
Laurie Kefalidis
The Daniel & Estrellita Brodsky Family Foundation
ICRAVE, LLC
Shuly and William Bron
Jefferies LLC
Richard J. Byrne
Sarah and Stewart Kagan
Latham & Watkins LLP
Cabana Life
The Kapnick Foundation
Jo Carole and Ronald Lauder
Gaston Caperton
Jill and Harry Kargman
Mizuho Securities USA, Inc.
William H. Carter
George Klein
Morgan Stanley
Thomas W. Cole
Jonathan Kolatch
Morgan, Lewis & Bockius LLP
James Connolly
Cheryl and Alvin Krongard
Paul Hastings
Frank Courtney
Kristen and Charles Krusen
Pfizer, Inc.
Crescent Capital Group
Lan Lecour
Lizanne and Barry Rosenstein
Kara and James Cross
Carolyn and Marc Rowan
Daryl & Steven Roth Foundation
Ashley Leeds and Christopher Harland
Alison Sarofim and Stuart Parr
Davis Polk & Wardwell
Almedena and Pablo Legorreta
Simpson Thacher & Bartlett LLP
Deutsche Bank
Susan and Eric Smidt
Eva and Brendan Dillon
The Loan Syndications & Trading Association (LSTA)
Mary and David Solomon
Susan Drossman and Adam Sokoloff
Kohlberg Kravis Roberts & Co. The Marie-JosĂŠe & Henry R. Kravis Foundation
The Thompson Family Foundation Eddie Trump UBS Mary Lynn and Bronson van Wyck Veritas Capital Management, LLC Leslie and Daniel Ziff
30
Supporters & Financials
GA Partners Foundation GE Capital George W. and Elizabeth W. Kelly Foundation, Inc. Gibson, Dunn & Crutcher LLP
Hazen Polsky Foundation
William Janetschek
Looney Legacy Foundation Howard M. Lorber
Kathryn and Philip Dunn
Peter J. Lyon
Scott Edelman
Priscilla and Connie Mack
Elizabeth Eielson
Macquarie Group
Erving and Joyce Wolf Foundation
Sue and Tom Mandel
Susan and Peter Evensen
Alison Mass and Sal Bommarito
Andrea and George Ferris
Christine and Joseph McGrath
Clare McKeon
Leanne and Richard Tavoso
Sara Ferchichi
Merck & Co., Inc.
Christopher J. Torrente
Deborah M. Festa
Richard N. Merkin
Daniel Toscano
James D. Forbes
Michael E. Michetti
Mindy and Marc Utay
Freeborn & Peters LLP
Stan Middleman
Thomas Wagner
Scot French
Christina P. Minnis
Deborah and Jeffrey Weber
Rondi and David Frieder
MJX Asset Management, LLC
Wells Fargo Bank
Kara Gaffney Ross and Stephen Ross
National Pharmaceutical Council
White & Case LLP
James Galowski
Natixis Global Asset Management
Karen and Gary Winnick
William Gates
Alexander Navab
Barbara and David Zalaznick
Peter Glaser Dev Gopalan
Margo and James Nederlander Patty Newburger and Brad Wechsler
$1,000-$4,999
Benjamin Grinberg
Nomura Securities
Lawrence B. Alletto
Mary and Meyer Grinberg
Amie and Scott Nuttall
Kevin Arnold
Lucy and Lawrence Guffey
Oak Hill Advisors, LP
Kathryn Bach
Renee Harbers and Chris Liddell
Peter O’Neill
Renee and Richard Barasch
Kristy and Robert Harteveldt
Orchard First Source Asset Management
Nicole and Ron Beit-Halachmy
William M. Hartnett
Bergdorf Goodman, Inc.
Christy Hedges
Craig Packer
Vadim Berman
Caroline Hirsch and Andrew Fox
Post Advisory Group, LLC
Big Orange Foundation
Molly Johnson
Provectus Pharmaceuticals, Inc.
Judy and Charles Black
Mark Kahn
The Reiss Family Foundation
BNP Paribas
Jason Kanner
Avis and Bruce Richards
David Boden
Kelly’s Dream
James Robinson
Bristol-Myers Squibb Foundation, Inc., The
Bonnie and Bradford Klein
Royal Bank of Canada Christopher Rulon-Miller
Timothy Broadbent
Adam Kurzer
Ron Sabatino
Elizabeth and Christopher Butler
Bret Leas
The Lawrence and Carol Saper Foundation
Bruce Car
Karen and Richard LeFrak
Trudy and Paul Cejas
Bruce Schachne
Lili Lynton and Michael Ryan
Patricia and Michael Chernick
Jane and Nelson Schwab
Earle I. Mack
Clare Hare Darien
Shearman & Sterling LLP
Robert Marotta
John Cokinos
Shenkman Capital Management, Inc.
MD Solarsciences Corp.
Bob Coors
Skadden, Arps, Slate, Meagher & Flom LLP
Medicomp Systems, Inc.
CORE Media Group
Judith F. Minter
Bradley W. Cuddeback
Mott 50 LLC
D.E.J. E., Inc. DBA Jimmy’s
George Mueller
Gilliam and Robert Steel
Jeanine Depasquale Salvatore and Louis Salvatore
Hutham Olayan and Robert Raucci
Alison and Leonard Stern
Charles Dubow
Stone Point Capital Foundation Inc.
Eaton Vance
Kelly and Jay Sugarman
Entrogen, Inc.
Sumitomo Mitsui Banking Corporation
Eric Javits, Inc.
Societe Generale Sony Music
Hope and Glenn Taitz
Mitchell Kline
Parasol Tyler Patterson Louise Perkins Sean H. Peters Prizeo
31
Jonathan Ressler
Clarke Adams
Diane Bengston
Nancy Risman
Veena and Sridhar Akenapally
Brad Benson
Brian Robbins
Sabina Albirt
Harold Benson
Jeffrey Rosen
Marilyn R. Alper
Sandy Benson
Robert Rowe
Joan and Lawrence Altman
Cindy Bergmann
David T. Rubulotta
Altus Group
Karen and Brian Berkley
William Rutkoske
Amica Companies Foundation
Eric Berkowitz
Pamela and Arthur Sanders
Franklin Amoo
Frederic Bernhard
Haley and Matthew Satnick
Josh Amoss
Jill Bettenhausen
Wendy and Michael Selig
Jill C. Anderson
Vitoria and John Betz
Kevin Sherlock
Ildiko Antal
Whitney Beutel
Doug G. Smith
Michael Antonovich
Chetan Bhandari
Manish Somaiya
Paul Arbo
Tina Bird
Ann and John Sorice
Brian Archer
Sanji Bizzarro
Adam Soufleris
Michael Arougheti
Ryan Blackney
Southmont JR.-SR. High School
Matthew Assiff
Sara Blakemore
Debora and James Staley
Alex Blau
Harriet and Ernest Steigman
Associated Jewish Charities of Baltimore
Meredith and Richard Steigman
Caroline J. Atherton
Jeffrey B. Bloom
Sun Protective Designer Clothing
Rachel Atterberry
Traci Otey Blunt
Pamela Sztybel and Elliott Stein
Anthony Aufiero
Dorothea Bobinski
Stephanie Teicher
Sharyar Aziz
John Boden
Fern and Leonard Tessler
Cristina C. Bacon
Rick Boden
W. Cade Thompson
H. Gordon Baier
Michael Bohigian
Adele Thurnher
Helen Baker
Sara Bolduc
Evelyn and Jon Tomasson
Susan and Jon Ballis
Wendy Bollinger
Tracy and Christopher Turner
Betsy Barclay
James Bonetti
Thomas Uger
Grant C. Barmby
Michelle Booden
Kevin Ulrich
Jessica Barr
Paul Borowski
Vineyard Vines, LLC
Juliet Barr
Jessica Botke
Trevor Watt
David Barth
Karen and Jon Boulanger
Abigail Wender
Christine Bartus
Seymour Boyers
Jeremiah Whiddon
Alan Bash
Edgar Braunstein
Scott Willard
Mark Basile
Todd Bredbenner
Rose and James Wolfe
Eugene Bass
Brelli
Brian Yorke
David Battle
Christiopher Brescio
Sandra J. Bauer
Carol and Robert Brewer
Brian Beal
Joan and Ronald Brook
Dana Abatemarco
Suzanne Beatty
Catherine and Christopher Abbate
Chris Becker
The Brooks Group and Associates, Inc.
Kathryn A. Abbott
Loren Becker
Susan and Mark Broude
Frank Adamo
Shirley and Denis Bellm
Tom Brown
i $1,000
32
Supporters & Financials
Roslyn and Allan Blau
Barbara Bull
Caryn Cohen Bilzin and Jonathan Bilzin
Carrie Diamond-Feldman and H. Leigh Feldman
Susanne Bull
Keith Cole
Dennis Dillon
John Burgess
Sherryl Coleman
Clarissa Dimperio
Christopher Burns
Tracy Coleman
Kirsten Dineen
Martha and Thomas Burns
David Colla
Michelle Dinenberg
Jennifer and Norm Burstein
Gia Colunga
Gina Diorio
Michael J. Burton
Wynne and Philippe Comer
Mark D. Director
Susan and Alan Bushell
Jerome Connolly
Donna Dolan
Amanda Buttenbusch
John Connor
Douglas Dolfie
David Cadigan
Carolyn and Grafflin Cook
Marcia and Frederick Donini
Matthew Campobasso
John Scott Cooke
Kevin Dowd
Brian Candee
George Corey
Donald G. Drapkin
Robert P. Candee
Edward Corletzi
Kim and Nick Drazic
W. Jane and Simon Canning
Deb Cornejo
Suzy Dritz
Rita Canova
Cosmopolitan Club of Santa Barbara, Inc.
Cecilia Ducharme
Elizabeth and Robert Craven
Linda J. Durand
Jay Creekmore
Robin Dusek
Marjorie C. Crichton
Joshua Easterly
Sondra Cristal
Richard Ebinger
Matthew Cudrin
J Edwards
Robin and Richard Cudrin
Eileen Elias
Cunningham Supply, Inc.
Karen Elizaga and Jay Ptashek
John Cushing
Melissa and Douglas Ellin
Cybergrants, Inc.
Margot and Brian Erlich
Sharon Dale
Dawn Eslinger
John D’Ambrosio
Winfield Essex
Bonnie L. Damron
Dan Esters
Brian Daniels
Sarah and Preston Everdell
Alice and Sabatino D’Ascanio
Jennifer and Michael Ezell
Kirk A. Davenport
Erik Falk
Corrinn Davis
Frances and David Fall
Robert Davis
Jeff Farber
Barbara and John Dawson
Kevin Farley
Teresa DeBenedictis Oakes
Catherine Farrell
Valerie and Daniel Delaney
Chris Fazio
Armand and Lauren Della Monica
Jim Feeley
Marie DeMasi
Jeanne Ferguson
Anne Dempsey
Stephen and Megan Ferraro
David DeSantis
Marcia Fettig
Victor Dhooge
Fidelity Charitable Gift Fund
Thomas Buch
Emily Carey Diana M. Carnemolla Alexandra Carney Anne Carnicelli Janice Carroll Richard Carty Joyce Caruthers John Cashman Joanne Chamberlain Gerald Chaney Mary Jane Chapline Michelle Chapman Barbara and Robert Charamut Randy Chase John Chaski Mario Checca Andrew Cheng Amy Chenski Gloria Childress Elizabeth Chorabik Eunu Chun Alison Clarke Class Reunion Of 1956 Kathleen Cleason Catherine Clements Kenneth Coffey
John Dunn
Gary Diamond
33
34
Marilyn and Larry Fields
Camille and Michael Gillespie
Rick Harris
Mary and John Filipkowski
Diane and Ronnie Gilomen
Dion Harrison
Alberta E. Findeisen
P. and Jerome Ginsburg
Mary Hart
Paul Finger
Michael Giordano
Harvard Community Gifts
Maryann Finley
Krista M. Giovacco
John F. Hasler
First Aid Beauty, LTD
Suzanne Glad
Cindy Hauer
First Mid-Illinois Bank & Trust
Laura Glennon
Kristen Haunss
D Geoffrey Fitton
Erika Goedrich
Brian Hayes
Ethelyn and Edwin Flick
Andrew L. Goldstein
Erin Healy
Joe Fogel
Mitchell Goldstein
Andrew Heller
Elyse Ford
Ronnie Goldstein
Neil Heller
Karen P. Forman
Michelle A. Golliday
Tonita Helton
Karen Fox
Debra Gonzalez
Pamela and Jonathan Henes
Stephen Fraidin
Virginia and Robert Good
Betty Rae Henno
Cathy Franczyk
Carrie Goodman
Edward J. Hensler
Leslie Frausto
Sam Goodyear
Victoria Herbert
Michael D. Freeborn
Faith and Richard Gordon
Don Hershberger
Sara Freeland
Marlene Gorke
Christopher J. Herzog
Holly Freeman
William R. Goshorn
Stephen E. Hessler
Gail and Mark Frey
Paula Granam
Kara Heydecker
Pamela and Kevin Frey
Thomas Gravina
Sean Hickey
Jan and Dan Froehlig
Greater Twin Cities United Way
Jack Hidary
Daniel Frommer
Alan Green
Lori and Michael Hiller
Matthew Fuller
Robert Green
Susan Hirschman
Robert Fullerton
Beatriz Greenberg
Abigail Hoehne
Robert Funk
Nicole L. Greenblatt
C. Holland
Anthony H. Gair
Jeffrey Greenip
Jacqueline Hollingsworth
Mary Lou and Donald Gallagher
Brenton Greer
LaVonne and Richard Holmes
Elliot Ganz
Ashley S. Gregory
Darrick Hooker
Zenin Ganzon
Patrick Horbac
Corey Geer
Barbara Grenzinski-Winalski and Stephen Winalski
Amy Gensler
Marc D. Grossman
Sally and Michael Horner
Teresa Gentile
Cynthia and Thomas Gutzler
Rosa and Daniel Horwath
Thomas George
Linda and Joel Hahn
Jill Howard
Nellie and James Gerlach
Vicki and Grant Haley
John Howard and Howard June
Brad Gerratt
Sadia Halim
Thomas M. Howard
Barbara D. Gholz
Lucy Halperin and Jerold Zaro
Kecia Howson
Bessie T. Giannopulos
Susan and Mark Hamlin
Gary and Michele Hughes
William Gianopoulos
John Hammerle
Amanda Hume
Kevin Gibbs
Robert Hammond
Earl Hunt
Robert Giblichman
Bernice and Dwight Harrelson
James Hussney
Lisa Giesler
Matthew Harrington
Yongjin Im
Supporters & Financials
Virginia M. Horn
Pyper Imperial
Ethan Klemperer
Gretchen Letson-Rask and Peter Rask
Internet Society
Fern and Arnold Klepner
Richard Levenson
Brian Iorio
John Kline
Greg Levi
Ira S and Anna Galkin Charitable Trust
Kyle and Martin Klostermann
Michelle Levy
Cindy and Ike Isenhour
Mishell B. Kneeland
Shery Levy
Joseph Jabes
Jacob Koering
Edward Lewis
Winifred Jackson
Jennifer M Koller
Maya Lin and Daniel Wolf
Sandra Janiga
Nancy and Joshua Korff
Alana Linsenbigler
Zachary Jarvis
Jean and Scott Korte
Kevin Lockhart
Katherine Jason
Chris Kovel
Brigette Loden
JBS international, Inc.
Matthew J. Kramer
Ronica Logani
Sarkis Jebejian
Summer Kramer
Brenda Lopez and Margaret Skubel
Mark Jenkins
Gail and Richard Krause
Sarah Lowe
Alison Jenks
Ann Krieger
Chiuwa E. Luk
Candace and Jeffrey Johnson
Patrick Kris
April Luka
Andy Jonusaitis
David Kroner
Kim Lundy
Judith Ripka Creations, Inc.
Donna Kronson
Bina Luther
Christina Junior
Ron Kubick
Van Ly
Joyce and Lawrence Kabat
Vinay Kumar
Matthew Lynch
Jarrod Kaplan
Kristen Kuroski
Lynne C. MacArthur
Lori Kaplan
Thomas Kuroski
Joseph P. Machuta
Rachel Kaplan and Howard Hershenhorn
Marlene B. Landon
Kris Maciorowski
Heather Lang
Deirdre Magarelli
Robert Kaplan
Joseph A. Lang
Matthew Magnuson
Joyce and Jerome Katz
Steven Lang
Michael Mahlstedt
Seth Katzenstein
Bill Langford
Arlene E. Maidman
Marcia Kaufman
Shirley LaPorte
Nancy and Steven Manket
Jeanne Kaump
Lee and Daryoush Larizadeh
William Manning
Wynne Keefer
Judith Larson
Punit Marathe
Marc Keislstein
Laura Lausier
Christopher Marcus
Billie Keitelman
Christopher Lawler
James Marshall
Robert Keller
Edgar Lawrence
Gene Martin
Sean Kelley
Michael Lawton
Patricia Martin
Jeff Kelly
Edward Lear
Gregory Mason
Alan Kennedy
Gowoon Lee
Mary and R. D. Mason
John Kilgallon
Mary K. Lee
Peter Mason
Carolyn Kilkenney and Ryan Kilkenny
Jeffrey Leen
Ronni Massok
Dawn and Tim Killenberg
Albert Lefkovits
Linda M. Mastrone
Kim Kimberlin
Lauren C. Leiman
Omer Masud
Andrew Kirby
David Lerner
Luanne Matarangas
John Kitson
Samuel Less
Jeff Mattson
Stacy Klein and Les Olin
Letarte Retail Greenwich LLC
Ann W. May
35
36
Scott McCallister
Bridget Murphy
Diane K. Palumbo
Maureen W. McCarthy
Donna Murphy
Alexander Pankov
Kimberly McConnell
Kevin Murray
Jeffrey Panzo
McCoy Family Trust
My Tribute Gift
Christian Paragot-Rieutort
Jo Ann McCoy
John Myer
Gregory Passaretti
Sean McDermott
Linda K. Myers
Amanda Pastre
Debra McDonald
Lisa Myers
Eleanor Pearce
Al McGhee
Shirley Myers
Margaret Pedone
Deirdre McGuinness
William Myers
Pepsico Foundation
Lori McKay
Donna Mylenek
The Perelson Family Trusts
Nina McNealey
Lauren Nadeau
April and Jim Perez
Bob McWilliams
Christian O. Nagler
Jaime Perez
Jo-Anne and Jacques MeilleurLamoureux
Cortney Nathanson
Darlene Pergola
Carol Nebel
Michelle and David Pestillo
Andres Mena
Michael Nechamkin
David Peters
David P. Mendez
Linda and Emil Nehrt
Janet Petkin
Jackson Merchant
Chris Neikirk
John Petrozzi
Merriam Sunshine Fund
Carol and John Nelson
Robert Pezzano
Kenneth Mersel
Cheryl Nelson
Alan Phillips
Megan Messina
Ronald W. Nelson
Janice Phipps
Andrew Messinger
Sally Nelson
Mark Pibl
Marcia Meth
Tom Newberry
Barbara Pieper
Daniel Meyer
Lila M. Newman
Laura Pieper and Adam Cullin
Jane and Charles Meyer
Maureen Newman
Michael T. Pierce
Kirstin and Carl Meyer
Pamela and George Nixon
Susan and Peter Pineault
Donna Michael
Leslie Nobile
Francisco Pinto-Leite
Matthew Michelini
Peter Nolan
The Plainville Wind Ensemble
Mike Middleman
Matt Nord
Kevin Pluff
Amy Miller
Patti Nordon
Justin Polselli
Catherine Miller
Morgan Nuckolls
Minna and Rob Pomeroy
James F Miller
Kathryn Oktavec
Katherine Pond
Tina L. Miller
Arthur Oles
Debra and Ronald Pook
Lillian Millette
Stephanie Oratz Basta and Paul Basta
Elizabeth Pook
Braxton Mitchell Christina Mohs
Karen Orfitelli
Christopher Porter
Patricia Monohan
Debora Oriolo
Karen and Lane Powell
Sandra Lee and Cromwell Montgomery
Michele S. Orndorff
Bart Powers
Tom Otto
Anna Morris
Janet Pozmantier
Diana and Peter Morse
Kimberly Owens Wise and John Wise
Jerianne Pugh
Michael Movsovich
Floyd G. Page
James Moyne
Randal Palach
Cheryl and Ronald Mueller
Catherine and Peter Palermo
Supporters & Financials
Alex Popov
Claire and Joseph Purcell Eman Quotah Frederick Raccosta
Jane and Richard Raczek
Verona Sandberg
Aleesha Smith
Kirk A. Radke
Geri and Neal Sanderson
Barry Smith
Howard R. Ragin
Paul Sandoli
Bram Smith
Robert T. Rahr
Wendy and Edward Sassower
Carol Smith and Christopher Walston
Frieda Ramaswamy
Matthew Savino
Charles Smith
Monika and Christine Rapp Dombrowski
Joanna Scales
Mitali Sohoni
Carl Scarpa
Mary Soldat
Lisa Rapuano
Elaine and Howard Schain
Linda Sommers
Susan and Steven Ratner
Sue and Kenneth Schechter
Juliet Son
Laura and Michael Redmond
Scott Schewe
William B. Sorabella
Jason Ridloff
Beth Schlansky
David Sorkin
Elizabeth W. Ring
Jenny Schmidt
Gregory Sparer
Lynn and Steven Ritchie
Phillip Schnell
Laura and Stephen Spencer
Steven Ritchie
Anne and Ray Schrock
George P. Stamas
James Roahen
Karen Schroeder
Nancy Stanley
William Robbins
Marcie and Douglas Schubert
Allison J. Steigman
Carol Roberts and Mary Hom
Mimi Schwartz
Spencer Stenmark
Margaret Roberts
Roberta Schwartz
Susan Sterk
Larry Robertson
Patricia Scott
Sean Stevens
Nancy Robertson
Ezra Segal
Glenn Stewart
Roger Robichaud
Karen and Steven Seltzer
James Stone
Ashley Robinson
Betty Serafin
Robert Stopher
Helene and Jonathan Rod
Randy Shacka
Kathryn Storm
Bruce Rokjer
John Shapiro
Sara Subhani
Robyn Roof
T.J. Sheahan
Phil Sutcliffe
Lesley and Bradford Rope
Jamie Shearer
Jenni Swan
B. J. Rosen
Jill R. Shellow
Maureen E. Sweeney
Paul Rosen
Natalie L. Sherling
John Sweeting
Mary-Claire Ross
Carolyn Shields
Debra and Paul Taaffe
Dean Rostovsky
Cindy Shoemaker
Ed Tam
Stacey Roth
Steven R. Shoemate
Ivana Tarsia
Susan Roth
Paul Sigfusson
Carson L. Taylor
Even Rothenberg
Pamela S. Silberman
Christopher Taylor
Griffin Rotman
Greg Silva
Janet and Richard Taylor
Ben B. Rubinowitz
Linda Silva
Robin and David Teh
Joseph Ryan
Chad Silver
Meghan Tepas
Mike Ryan
Karen and Dennis Simmons
Ernita Thomas
Wendy Sacks
Beverly B. Simpson
Kathryn Thomas
Alex Sade
Margot and C. Simpson
Mark Thovson
Peter Saghir
Mike Simpson
Deborah W. Tiedrich
Peter Sakon
Wendy and Todd Sinett
DonnaLee and George Tignor
Terry Sanabria
Anthony Smeraglinolo
John Timperio
37
Robert Tintner
Nick Whitney
Linda Tishler
Michael Wiggins
Jeffrey Titus
Kenneth Wiley
Michael Tomasek
Kirsten Wilkins
Linda Torrey
Jajuanna Williams
Christine C. Totman
Richard Williams
Christina and Peter Toto
Whit Williams
Michael Townsell
Garry Wills
Sara Traberman
Joseph Wilson
Edward Trageser
Ray Winborne
Jeremy Traska
Lenore Windsor
Travelers
Valorie Winkelman
John Trentos Kiran Trivedi
Nancy Winkelstein and Christopher Plaut
Joe and Dale Trott
Joseph J. Winowiecki
Catherine Twitmyer
Trevor Winstead
Kathy and Joseph Valentine
Robert Wise
Nipa Vatsaraj
Beverly and Henry Wlodkowski
Robert Von Ancken
Brian Wolfe
Daniel Vose
Ira Wolfe
Randy Wadle
Kip Wolfe
Doug Wagner
Frances and Raymond Wolski
Kathleen Wagner
Christina Wong
Leon Wagner
Scott Woodworth
Roberta Wald
Patrick Woytek
Heather Walters
Michael Wright
Amaris Wang
Kathy Wuebbels
Lisa W. Wardell
Debbie and Brian Wulfson
Jason Wasdin
Caesar Wyszomirski
Heather Webb
Joe Yocom and Henry Woodside
Joseph Webb
You Beauty
Marvin Weinbaum
Kenneth Young
Geralyn and Gerald Weis
Maggie Young
Cynthia Weisbard
Kristen Zachariev
Wendy Weisbard
Kimberly Zahour
Eric Weiss
Craig Zaph
Jill Weiss
Taurie Zeitzer and Goran Mihajlovic
Patrick Wellspeak
Gene Zelek
Margaret Welsh and David Johnsen
Jim Zilisch
Lynn Wenzel
Margaret and John Zucker
Medina White
Tony Zumbo
Thomas Whitley
38
Supporters & Financials
Board of Directors Debra Black (Chair) Co-Founder – MRA; Phaidon Press Leon Black Co-Founder – MRA; Chairman, Chief Executive Officer and Director – Apollo Management LP Maria Bell TV Writer and Producer Ellen Davis Founder and Chair – JCC Greenwich; President – UJA Greenwich Amanda Eilian Co-Founder and President – Videolicious (The Talk Market Inc.) Jason Federici Art Director, Graphic Designer and Photographer Jami Gertz TV and Film Actress Susan Hess Vice Chairman – Whitney Museum Michael Klowden Chief Executive Officer – Milken Institute Connie Mack III Senior Policy Advisor – Liberty Partners Group LLC Nancy Marks Chairman – Ralph Rucci Cindy McCain Humanitarian and Businesswoman Michael Milken Chairman – Milken Institute Richard Ressler Founder and President – Orchard Capital Corporation; Co-Founder – CIM Group
Jeffrey Rowbottom Managing Director – Kohlberg Kravis Roberts & Co. Elliott Sigal, M.D., Ph.D. Former Executive VP and Chief Scientific Officer – Bristol-Myers Squibb Greg Simon Chief Executive Officer – Poliwogg Jonathan W. Simons, M.D. President and Chief Executive Officer, David H. Koch Chair – Prostate Cancer Foundation Jonathan Sokoloff Managing Partner – Leonard Green & Partners, LP Liz Stanton President – Oliver and Elizabeth Stanton Foundation Suzanne Topalian, M.D. Professor of Surgery and Oncology; Director, Melanoma Program, Sidney Kimmel Comprehensive Cancer Center – Johns Hopkins University
Staff (non-Director): Wendy Selig President and Chief Executive Officer – Melanoma Research Alliance
Officers (non-Director): Officers (non-Director)
Margaret Anderson (Secretary) Executive Director – FasterCures Kamyab Hashemi-Nejad (Treasurer) Director of Finance – Milken Institute
39
Committees Scientific Advisory Panel (2014) The MRA Scientific Advisory Panel advises, assists, and makes recommendations to the MRA leadership team on scientific matters and policies, including research needs and opportunities that may be targeted for funding and scientific symposia. Suzanne Topalian, M.D. (Chair) Professor of Surgery and Oncology; Director, Melanoma Program, Sidney Kimmel Comprehensive Cancer Center – Johns Hopkins University
Richard Gaynor, M.D. Vice President, Oncology, Product Development and Medical Affairs – Eli Lilly and Company Michael Giordano, M.D. Senior Vice President, Oncology and Immunosciences Development – Bristol-Myers Squibb Jeffrey Legos, Ph.D. Medicines Development Leader – GlaxoSmithKline Neal Rosen, M.D., Ph.D. Enid A. Haupt Chair in Medical Oncology – Memorial Sloan Kettering Cancer Center
James Allison, Ph.D. Chairman, Department of Immunology; Director, Immunotherapy Platform; Deputy Director, David H. Koch Center for Applied Research of Genitourinary Cancers – University of Texas MD Anderson Cancer Center
Grant Review Committee (2014) MRA’s Grant Review Committee, composed of leading experts in melanoma and cancer research, is responsible for vetting all research proposals we submit. Review is based on MRA’s key criteria: innovation, scientific merit, and potential for rapid progression to clinical testing. MRA’s conflict-of-interest guidelines ensure a fair and unbiased progress. Final funding decisions are ratified by the MRA Board of Directors. David Solit, M.D. (Chair) Associate Attending Physician, Genitourinary Oncology Service; Associate Member, Human Oncology and Pathogenesis Program – Memorial Sloan Kettering Cancer Center
Steven Rosenberg, M.D. Chief, Surgery Branch – National Cancer Institute, National Institutes of Health
Kim Margolin, M.D. (Co-chair) Physician, Department of Medicine – University of Washington/Seattle Cancer Center
Mace Rothenberg, M.D. Christopher Austin, M.D. Director – National Center for Advancing Translational Sciences, National Institutes of Health Boris Bastian, M.D. Clinical Professor, Department Dermatology – University of California, San Francisco
Senior Vice President and Chief Medical Officer – Pfizer Oncology Joshua Sharfstein, M.D.
Steven Burakoff, M.D.
Ellen Sigal, Ph.D.
Professor of Medicine, Hematology and Medical Oncology; Professor, Oncological Sciences – Mount Sinai School of Medicine
Chairperson and Founder – Friends of Cancer Research
Chief Medical Officer – Omicia
Steven Stein, M.D.
Gideon Bollag, Ph.D.
Senior Vice President, US Clinical Development and Medical Affairs – Novartis Oncology
Lynda Chin, M.D. Professor; Chair, Department of Genomic Medicine; Scientific Director, Institute for Applied Cancer Science – University of Texas MD Anderson Cancer Center
40
Associate Professor of Dermatology and Pathology – Yale School of Medicine
Secretary of Health and Mental Hygiene – State of Maryland
Paul Billings, M.D., Ph.D.
Chief Executive Officer – Plexxikon
Marcus Bosenberg, M.D., Ph.D.
Michael Weber, Ph.D. Professor of Microbiology, Immunology and Cancer Biology, Weaver Professor of Oncology – University of Virginia
Paul Chapman, M.D. Attending Physician, Melanoma/ Sarcoma Service – Memorial Sloan Kettering Cancer Center Tanja de Gruijl, Ph.D. Associate Professor – VU University Medical Center
Charles Drake, M.D., Ph.D.
Thomas Hornyak, M.D., Ph.D.
Antoni Ribas M.D., Ph.D.
Associate Professor, Oncology, Immunology and Urology; Director – Multidisciplinary Prostate Cancer Clinic, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Chief, Dermatology, VA Maryland Health Care System; Associate Professor of Dermatology and Biochemistry and Molecular Biology – University of Maryland School of Medicine
Associate Professor, Department of Medicine – University of California, Los Angeles
Glenn Dranoff, M.D. Director, Human Gene Transfer Laboratory Core – Dana-Farber Cancer Institute David Fisher, M.D., Ph.D. Chief, Dermatology Service; Director, Melanoma Program, Massachusetts General Hospital Cancer Center; Director, Cutaneous Biology Research Center – Massachusetts General Hospital Thomas Gajewski, M.D., Ph.D. Associate Professor, Departments of Pathology and Medicine; Director, Immunology and Cancer Program – University of Chicago Comprehensive Cancer Center Levi Garraway, M.D., Ph.D. Associate Professor of Medicine – Dana-Farber Cancer Institute; Associate Member – Broad Institute Jeffrey Gershenwald, M.D. Professor, Department of Surgical Oncology, Division of Surgery – University of Texas MD Anderson Cancer Center
Roger Lo, M.D., Ph.D. Director, Melanoma Clinic in Dermatology; Assistant Professor, Department of Medicine, Dermatology; Assistant Professor, Department of Molecular and Medical Pharmacology – University of California, Los Angeles, School of Medicine Michal Lotem, M.D. Senior Physician, Sharett Institute of Oncology – Hadassah Hebrew University Hospital Richard Marais, Ph.D. Director – Paterson Institute for Cancer Research Grant McArthur, M.B.B.S., Ph.D., F.R.A.C.P. Professor; Co-Chair, Melanoma and Skin Service; Head, Molecular Oncology Laboratory; Head, Translational Research Laboratory – Peter MacCallum Cancer Centre Martin McMahon, Ph.D. Professor-In-Residence – University of California, San Francisco
Allan C. Halpern, M.D.
Glenn Merlino, Ph.D.
Chief, Dermatology Service – Memorial Sloan Kettering Cancer Center
Chief, Laboratory of Cancer Biology and Genetics – National Cancer Institute, National Institutes of Health
Stan Riddell, M.D. Member, Department of Immunology – Fred Hutchinson Cancer Research Center Caroline Robert, M.D., Ph.D. Professor of Dermatology, Head of the Dermatology Unit – Institute Gustave Roussy Lynn Schuchter, M.D. C. Willard Robinson Professor of Hematology-Oncology; Attending Physician, Hospital of the University of Pennsylvania; Program Leader, Melanoma Program, Abramson Cancer Center of the University of Pennsylvania; Division Chief, Hematology-Oncology – University of Pennsylvania Jonathan Simons, M.D. Chief Executive Officer and President, David H. Koch Chair – Prostate Cancer Foundation Alan Spatz, M.D. Professor – Jewish General Hospital/ Lady Davis Institute for Medical Research Suzanne Topalian, M.D. Professor of Surgery and Oncology; Director, Melanoma Program, Sidney Kimmel Comprehensive Cancer Center – Johns Hopkins University
Meenhard Herlyn, D.V.M., D.Sc. Professor and Program Leader, Molecular and Cellular Oncogenesis Program – The Wistar Institute
Drew Pardoll, M.D., Ph.D. Co-Director, Cancer Immunology and Hematopoiesis Program; Professor of Oncology, Medicine, Pathology, and Molecular Biology and Genetics – John Hopkins University School of Medicine
41
Medical Advisory Committee (2014) The MRA Medical Advisory Panel advises the MRA leadership team on medical matters and policies including medical consultations, clinical research needs and opportunities, clinical regulatory and policy initiatives, and public education about melanoma. Paul Chapman, M.D. (Chair) Attending Physician, Melanoma/ Sarcoma Service – Memorial Sloan Kettering Cancer Center David Fisher, M.D. Chief, Dermatology Service; Director, Melanoma Program, Massachusetts General Hospital Cancer Center; Director, Cutaneous Biology Research Center – Massachusetts General Hospital
Roger Lo, M.D., Ph.D.
Suzanne Topalian, M.D.
Director, Melanoma Clinic in Dermatology; Assistant Professor, Department of Medicine, Dermatology; Assistant Professor, Department of Molecular and Medical Pharmacology – University of California, Los Angeles, School of Medicine
Professor of Surgery and Oncology; Director, Melanoma Program, Sidney Kimmel Comprehensive Cancer Center – Johns Hopkins University
Patricia LoRusso, D.O. Professor of Medicine; Associate Director of Innovative Medicine – Yale Cancer Center
Physician, Department of Medicine – University of Washington/Seattle Cancer Center David Polsky, M.D., Ph.D.
Thomas Gajewski, M.D., Ph.D. Professor, Departments of Pathology and Medicine – University of Chicago
Antoni Ribas, M.D., Ph.D.
Professor, Department of Surgical Oncology, Division of Surgery – University of Texas MD Anderson Cancer Center F. Stephen Hodi, M.D. Associate Professor, Department of Medicine – Harvard Medical School; Director, Melanoma Center – DanaFarber Cancer Institute
42
MRA Staff
President and Chief Executive Officer Louise M. Perkins, Ph.D. Chief Science Officer Laura M. Brockway-Lunardi, Ph.D. Scientific Program Director Lauren C. Leiman Director of Marketing and Development
Associate Professor, Department of Medicine – University of California, Los Angeles
Alexandra Carney
Lynn Schuchter, M.D.
Jennifer Engel
C. Willard Robinson Professor of Hematology-Oncology; Attending Physician, Hospital of the University of Pennsylvania; Program Leader, Melanoma Program, Abramson Cancer Center of the University of Pennsylvania; Division Chief, Hematology-Oncology – University of Pennsylvania
Development Manager, Foundations and Campaigns
Sancy Leachman, M.D., Ph.D. Professor and Chair, Department of Dermatology; Director, Melanoma Research Program, Knight Cancer Institute – Oregon Health and Science University
Associate Attending – Memorial Sloan Kettering Cancer Center
Wendy K.D. Selig Kim Margolin, M.D.
Associate Professor of Dermatology and Pathology; Director, Pigmented Lesion Section – New York University Langone Medical Center, Joan and Joel Smilow Research Center
Jeffrey Gershenwald, M.D.
Jedd Wolchok, M.D., Ph.D.
Susan Swetter, M.D. Professor of Dermatology; Director, Pigmented Lesion and Melanoma Program – Stanford University Medical Center and Cancer Institute
Scientific Program Manager
Randy E. Marsh Executive and Operations Manager Henry Woodside Development Manager, CRM and Donor Communications
Statement of Financial Position
Thanks to the generous financial support of MRA’s founders for administrative and fundraising expenses, 100 percent of donations to MRA directly support melanoma research. The independently audited financial statements of the Melanoma Research Alliance Foundation form the basis of the following information.
December 31, 2013 With Summarized Totals at December 31, 2012
2013
Assets
Unrestricted
Temporarily Restricted
Total
Total 2012
Cash
$12,994,760
$1,320,099
$14,314,859
$10,961,694
-
21,158,458
21,158,458
19,806,654
Prepaid Expenses and Other Assets
50,739
-
50,739
81,832
Prepaid and Equipment (Net)
41,846
-
41,846
27,278
$13,087,345
$22,478,557
$35,565,902
$30,877,458
$218,230
-
$218,230
$169,506
120,000
-
120,000
50,000
1,684
-
1,684
321,412
339,914
-
339,914
540,918
12,747,431
-
12,747,431
9,392,603
-
22,478,557
22,478,557
20,943,937
12,747,431
22,478,557
35,225,988
30,336,540
$13,087,345
$22,478,557
$35,565,902
$30,877,458
Contributions Receivable (Net)
Total Assets
Liabilities and Net Assets Liabilities Accounts Payable and Accrued Liabilities Deferred Revenue Due to Affiliate
Total Liabilities
Net Assets Unrestricted Temporarily Restricted Total Net Assets
Total Liabilities and Net Assets
43
Statement of Activities Year Ended December 31, 2013 With Summarized Totals for the Year Ended December 31, 2012
2013
Revenues, Public Support and Other Income
Unrestricted
Temporarily Restricted
Total
Total 2012
$1,082,148
$7,030,450
$8,112,598
$3,664,602
3,989,318
3,294,000
7,283,318
4,666,666
Sponsorships
161,250
-
161,250
207,500
Interst Income
38,065
-
38,065
29,985
In-Kind Contribution
-
-
-
69,178
Other Income
-
-
-
54,500
Purpose Restrictions
1,265,102
(1,265,102)
-
-
Time Restrictions
7,524,727
(7,524,727)
-
-
14,060,610
1,534,621
15,595,231
8,692,431
9,650,631
-
9,650,631
8,476,752
Management and General
372,512
-
372,512
375,042
Fundraising
682,640
-
682,640
485,653
Total Functional Expenses
10,705,783
-
10,705,783
9,337,447
Change in Net Assets
3,354,827
1,534,621
4,889,448
(645,016)
Net Assets - Beginning of Year
9,393,604
20,943,936
30,336,540
30,981,556
$12,747,431
$22,478,557
$35,225,988
$30,336,540
Contributions Special Events (Net of Cost of Direct Donor Benefits of $329,582)
Net Assets Released from
Total Revenues, Public Support and Other Income
Functional Expenses Program Services
Net Assets - End of Year
44
1101 New York Avenue, NW, Suite 620 Washington, DC 20005 curemelanoma.org info@curemelanoma.org